篇名

基因溯源公司與製藥公司簽署共享數據合作協議   免費試閱

並列篇名

Popular DNA Testing Company Signs $300 Million Deal With Pharmaceutical Company

作者
中文摘要

製藥公司正尋求可以「修復」治癒或大幅減少流行性疾病之基因新藥。如歐美許多民眾使用23andMe(或Ancestry.com)等商品服務來了解他們的祖先。許多基因檢測跨足醫藥的公司,目前已經把重點放在:目標並非研發基於動物模型之藥物而係根據人類之數據去決定藥物。製造商23andMe透過承包商收集得到去辨識的BigData及進步的電算能力、雲端技術,使用其DNA資料研發藥物,卻開始浮出包括資料隱私和安全及缺乏透明度的限制或疑慮;且可預測的是,未來製藥公司將開始強迫人們採取特定基因療法—以「預防」和「根除疾病」為名。

英文摘要

The pharmaceutical industries are seeking for a new drug that can “repair” genes which cure or drastically reduce degenerative diseases. Many people in Europe and America use services such as 23andMe (or Ancestry.com) to learn about their heritages. The use of DNA data collected by 23andMe is not to develop drugs that are of animal-based model but rather based on human data. This is beginning to have an impact the current limitations including privacy and security, and lack of transparency on drug developing. Predictably, these pharmacists companies will begin forcing people to take specific DNA medications to help thwart disease—in the name of “prevention” and “disease eradication.”

起訖頁

148-157

出版單位
DOI

10.3966/241553062020060044015  複製DOI  DOI查詢

QRCode

下一篇
數位整合服務
產品服務
讀者服務專線:+886-2-23756688   傳真:+886-2-23318496   地址:臺北市館前路28號7樓

Copyright © 元照出版 All rights reserved. 版權所有,禁止轉貼節錄
TOP